NewAmsterdam Pharma (NAMS) plans Rule 144 sale of 11,582 shares.

Rhea-AI Filing Summary

A holder of NewAmsterdam Pharma Company N.V. has filed a notice to sell ordinary shares under Rule 144. The notice covers 11,582 ordinary shares to be sold through J.P. Morgan Securities LLC, with an aggregate market value of $410,888.61, on the NASDAQ around 01/07/2026. The filing states that there were 113,390,000 shares outstanding. The seller acquired 41,177 ordinary shares from NewAmsterdam Pharma on 01/06/2026 through the vesting of a restricted stock unit (RSU) grant, with the nature of payment described as RSU vesting.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary Shares	J.P. Morgan Securities LLC 270 Park Ave 10th Floor New York NY 10017	11582	410888.61	113390000	01/07/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares	01/06/2026	Vesting of RSU Grant	NewAmsterdam Pharma Company N.V. (issuer)			41177	01/06/2026	RSU Vesting

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does NewAmsterdam Pharma (NAMS) disclose in this Form 144?

The notice discloses a planned sale of 11,582 NewAmsterdam Pharma ordinary shares under Rule 144 through J.P. Morgan Securities LLC, with an aggregate market value of $410,888.61 on NASDAQ.

How many NewAmsterdam Pharma shares are planned to be sold and on what exchange?

The filing covers the planned sale of 11,582 ordinary shares of NewAmsterdam Pharma, to be sold on the NASDAQ stock market.

What is the aggregate market value of the NewAmsterdam Pharma shares in this Form 144?

The aggregate market value of the 11,582 ordinary shares covered by the notice is reported as $410,888.61.

When is the approximate sale date for the NewAmsterdam Pharma shares?

The notice lists an approximate date of sale of 01/07/2026 for the planned Rule 144 transaction.

How and when were the NewAmsterdam Pharma shares being sold acquired?

The filing shows that 41,177 ordinary shares were acquired on 01/06/2026 from NewAmsterdam Pharma Company N.V. via the vesting of an RSU grant, with the nature of payment described as RSU vesting.

How many NewAmsterdam Pharma shares were outstanding according to the notice?

The notice states that 113,390,000 ordinary shares of NewAmsterdam Pharma were outstanding at the time referenced in the form.